Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 10Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Pathologic Complete Response 1Neoplasms 1Neoplasm Metastasis 1Hemangiosarcoma 1HER2-positive Breast Cancer 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 92Cisplatin 70Oxaliplatin 37Capecitabine 37durvalumab 29Fluorouracil 26pembrolizumab 24Leucovorin 22S 1 (combination) 18Nivolumab 13Irinotecan 13Bevacizumab 13lenvatinib 12tremelimumab 10apatinib 8Trastuzumab 7Injections 7Albumin-Bound Paclitaxel 7130-nm albumin-bound paclitaxel 7Paclitaxel 6Immune Checkpoint Inhibitors 6Docetaxel 6titanium silicide 5surufatinib 5envafolimab 5camrelizumab 5atezolizumab 5Folfox protocol 5Drug Therapy 5Carboplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Biliary Tract Neoplasms × ARX788 × Clear all
NCT05041972 2022-09-13

ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)

Ambrx, Inc.

Phase 2 Withdrawn
BreastGastrointestinalThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡